Morgan Stanley Reiterates Equalweight Rating on Solventum (SOLV)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/19/2026
- Nasdaq climbs as chip and AI-linked stocks bounce back
- U.S. economy is "booming," JPMorgan’s Dimon says
- Musk pledges one share of SpaceX to every U.S. child
- Brent crude edges lower, even after Houthi attacks on Saudi infrastructure
- Prepare to buy the dip as U.S. stock selloff nears its end: Morgan Stanley
BTIG Starts Solventum (SOLV) at Neutral
September 5, 2024 5:40 AM EDTBTIG analyst Ryan Zimmerman initiates coverage on Solventum (NYSE: SOLV) with a Neutral rating.
The analyst comments "Solventum was spun out of 3M (MMM, Not Rated) in April 2024, creating a global healthcare company that operates in a variety of medical technology segments including Medical/Surgical, Dental, Health Information Systems, and Purification & Filtration with global sales of $8.2B and total addressable markets of $93B+. Historically the business segments within MMM underperformed and... More



